AI in healthcare, tobacco taxation, water safety failures, mental health gaps, key policies, research updates and more ...

GH Research ( ($GHRS) ) just unveiled an update. On January 5, 2026, GH Research announced that the U.S. Food and Drug Administration lifted the ...

To sum up, GH001 has shown us pretty robust efficacy, a strong safety profile, and durable antidepressant effects. Going into ...

New Jersey is poised to become one of the first states on the East Coast to establish a regulated framework for psilocybin-assisted therapy. On Nov. 24, the Assembly Health Committee approved Assembly ...

Detailed price information for Nrx Pharmaceuticals Inc (NRXP-Q) from The Globe and Mail including charting and trades.

Depression in middle age has previously been linked to an increased risk of dementia. But this relationship appears to be driven by a small cluster of six specific symptoms, rather than by depression ...

Addressing major unmet needs in mental health with pharmacology rooted in emerging and clinically validated neuropsychiatric biology * Lead progra ...

(NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced 80% completion of enrollment in ...

People with depression have a more than doubled risk of developing epilepsy, a new study says. Worse, depression then makes epilepsy more difficult to treat, a second study found. Both papers, ...

It’s the age-old debate — at what age should kids get a cellphone? The downsides of too much screen time are well-documented, with increased anxiety, eye strain and poor attention span among the chief ...

Recent studies of psychedelic therapy, using substances like psilocybin and lysergic acid diethylamide, or LSD, show rapid and lasting improvements to conditions like depression and addiction. One ...